In October, the Company announced multiple abstracts (one oral and three posters) highlighting new hepatitis B data were accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® taking place virtually from November 12-15. New data highlights include:
24-week on-treatment data from a Phase 2 trial evaluating VIR-2218 in combination with pegylated interferon-alpha (PEG-IFN-α) (Oral presentation; Abstract #26144).